Does SHBG rs6259 increase SHBG and lower free testosterone?

Sex hormone-binding globulin (SHBG) is a primary regulator of systemic androgen bioactivity. For adult males, understanding the genetic and physiological factors influencing SHBG is critical for evaluating functional androgen status.

Biophysical and physiological effects

• High-affinity sequestration: SHBG binds circulating testosterone with high affinity ($K_a \approx 0.6 \times 10^9$ to $1.2 \times 10^9$ L/mol). Typically, only 1% to 2% of testosterone remains completely free in circulation.
• Reduced bioavailability: Elevated SHBG levels shift the binding equilibrium, directly reducing both the free and weakly albumin-bound (bioavailable) testosterone fractions.
• Impaired tissue signaling: In line with the free hormone hypothesis, only bioavailable testosterone diffuses into target tissues. High SHBG restricts this active pool, blunting intracellular androgen receptor signaling in target tissues and potentially triggering symptoms of functional hypogonadism.

Genetic and molecular mechanisms

• The rs6259 variant: The rs6259 (G→A) missense polymorphism leads to an aspartic-acid-to-asparagine (Asp327Asn) substitution in the SHBG protein.
• Glycosylation and half-life: This mutation introduces an additional consensus N-linked glycosylation site near the C-terminus of the mature protein. This extra glycan structurally slows hepatic clearance and prolongs the circulatory half-life of SHBG.
• Circulating levels: Consequently, clinical cohorts and genome-wide association studies show that rs6259 carriers exhibit 10% to 20% higher steady-state circulating SHBG levels. While this shifts more testosterone into a bound state—often raising total testosterone levels—it restricts the free fraction, which is also associated with protective metabolic profiles, including reduced risks of type 2 diabetes.

Bottom line

• The SHBG rs6259 variant increases circulating SHBG levels by 10% to 20% by prolonging protein half-life via an extra N-glycosylation site. This elevation reduces the free and bioavailable testosterone fractions, directly limiting the hormone available for tissue-level androgen signaling.